Clinical efficacy of direct-acting antiviral therapy for recurrent hepatitis C virus infection after liver transplantation in patients with hepatocellular carcinoma

Figure 1 Numbers and percentages of the study patients who had responses to (n = 100) and failure of (n = 100) the 16 direct-acting antiviral regimens. EBR: Elbasvir; GZR: Grazoprevir; PrOD: Paritaprevir-ritonavir-ombitasvir-dasabuvir; SIM: Simeprevir.

Figure 2 mean (± SD) alanine aminotransferase levels in patients who had direct-acting antiviral therapy responses and failure (baseline, week 4, week 8, and week 12).

Figure 3 mean (± SD) platelet counts in patients who had direct-acting antiviral therapy responses and failure (baseline, week 4, week 8, and week 12).